Ligand validation:6F9R

PE8: 3,6,9,12,15,18,21-HEPTAOXATRICOSANE-1,23-DIOL

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6F9R_PE8_B_721	56%	76%	0.117	0.888	0.52	0.42	-	-	1	0	100%	1
9H1B_PE8_B_702	42%	92%	0.136	0.852	0.28	0.23	-	-	0	0	100%	1
7Q26_PE8_B_704	23%	84%	0.167	0.787	0.54	0.23	-	-	0	0	100%	1
3L9V_PE8_A_1	98%	37%	0.063	0.982	0.59	1.85	-	7	3	0	100%	1
7EKV_PE8_A_202	73%	79%	0.118	0.945	0.51	0.36	-	-	2	0	100%	1
4EY4_PE8_B_608	71%	41%	0.09	0.909	0.64	1.64	-	1	1	0	100%	1
5J2Z_PE8_A_513	70%	72%	0.122	0.94	0.55	0.55	-	-	4	0	100%	1
4D1G_PE8_G_1346	69%	73%	0.119	0.932	0.5	0.54	-	-	2	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.